Reven today announced the provisional acceptance and early online publication of a peer-reviewed article authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and his academic collaborators in the medical journal, Frontiers in Nutrition … Read More
Author Archives: Administrator
Reven Pharmaceuticals Wins FDA Approval of its IND Application for Treatment of COVID-19 With Rejuveinix (RJX)
| Featured
Reven today announced that the U.S Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application in connection with its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) as a potential treatment for COVID-19 patients … Read More
Reven Strengthens its Clinical Team with Three New Members
| Featured
Reven today announced that three new members with extensive experience and knowledge in clinical research and quality assurance have joined its multi-disciplinary team to work on the COVID-19 clinical project … Read More
Reven Selects E-Clinical Services Provider DSG for Clinical Data Management Services
| Featured
Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. … Read More
Reven Selects APCER Life Sciences as Its Service Provider in Pharmacovigilance, Safety Monitoring, Quality Assurance and Regulatory Affairs for Its Upcoming COVID-19 Clinical Trial
| Featured
Reven today announced that it selected the global specialty drug safety services provider APCER Life Sciences (APCER) as its preferred vendor to provide pharmacovigilance (PVG), safety monitoring, quality assurance and … Read More
US Patent and Trademark Office Allows Reven’s Patent Application to Issue as a New Patent
| Featured
Reven today announced that it received a formal Notice of Allowance from the US Patent and Trademark Office regarding its patent application entitled: “Compositions and Methods for the Prevention and Treatment of Cardiovascular Disease … Read More
Reven’s Patented, First-in-Class Anti-inflammatory Treatment Platform for Sepsis on Track for Clinical Testing in COVID-19 Patients
| Featured
Reven had recently submitted a Pre-Investigational New Drug (Pre-IND) application to the U.S. Food and Drug Administration (FDA) to obtain feedback and guidance for its clinical evaluation of the anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. Reven today announced that FDA has responded favorably to its Pre-IND application … Read More
Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform
| Featured
Reven today announced the publication of two peer-reviewed expert articles authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London) … Read More
Rationale for a randomized, placebo-controlled, Phase 2 study of Rejuveinix (RJX) in COVID-19 patients with acute lung injury and hypoxemic respiratory failure
| Featured
New drug products that can effectively improve the ability of supportive care to reduce the risk of ARDS or its mortality rate in COVID-19 patients are urgently needed. Rejuveinix (RJX) is a formulation of physiologically compatible active ingredients, including … Read More
Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D. Ph.D., Internationally Recognized for his Seminal Contributions to Oncology, Immunology and Immunity, as its Chief Medical Officer and Chief Scientific Officer
| Featured
In his new position at Reven, Dr. Uckun will provide executive oversight for Reven’s global Research & Development and clinical programs. In addition, Dr. Uckun will contribute medical-scientific leadership and direction for Reven’s basic and translational research activities … Read More
Mitochondrial function and toxicity: Role of the B vitamin family on mitochondrial energy metabolism
| Featured
The B vitamins are water-soluble vitamins required as coenzymes for enzymes essential for cell function. This review focuses on their essential role in maintaining mitochondrial function and on how mitochondria are compromised by a deficiency of any B vitamin … Read More
Rejuveinix (RJX) as a drug candidate for patients with systemic inflammatory response syndrome (SIRS): Supportive care considerations for COVID-19, cancer, and sepsis
| Featured
Sepsis is the consequence of a systemic host inflammatory response to an infection with bacteria, fungi or viruses that is further associated with profound metabolic alterations (1-9). Severe sepsis is frequently associated
with septic shock … Read More
Reven Announces COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Regulatory Update
| Featured
Golden, Colorado, Thursday, June 11, 2020 1:00am MDT – Reven, LLC, a biopharmaceutical company that is developing Rejuveinix (RJX) for patients with cardiovascular and other health conditions, announced today that it recently completed an animal study in connection with its … Read More
Effect of diet composition on acid–base balance in adolescents, young adults and elderly at rest and during exercise
| Featured
A diet containing plenty of animal proteins and cereal grains and deficient in vegetables and fruits–a typical diet for many Westernized cultures … Read More
The Alkaline Diet: Is There Evidence That an Alkaline pH Diet Benefits Health?
| Featured
Life on earth depends on appropriate pH levels in and around living organisms and cells. Human life requires a tightly controlled pH level … Read More